SHERIDAN, WYOMING – May 8, 2025 – Alcon Inc. (SIX/NYSE: ALC), the global leader in eye care, today revealed the successful outcome of all proposed resolutions at its 2025 Annual General Meeting (AGM). Among the significant decisions, shareholders approved key appointments to the Board, including the election of Deborah Di Sanzo, and granted approval for the 2024 Compensation Report and the Report on Non-Financial Matters.
Key Appointments and Re-elections
At the 2025 AGM, shareholders re-elected F. Michael Ball as Chair of the Board of Directors, alongside several other members who stood for re-election. This includes Lynn Bleil, Arthur Cummings, David Endicott, Thomas Glanzmann, D. Keith Grossman, Scott Maw, Karen May, Ines Pöschel, and Dieter Spälti. These appointments ensure the continued leadership and strategic direction of Alcon for the upcoming term.
Furthermore, Deborah Di Sanzo was elected to join the Board, with her term set to begin on September 1, 2025. Her appointment adds a new dimension of expertise to the leadership team.
Shareholder Approvals and Reports
During the AGM, shareholders also approved the maximum compensation amounts for the Board of Directors and the Executive Committee for the upcoming terms. These approvals reflect the ongoing commitment to aligning executive compensation with the company’s long-term performance goals.
The 2024 Report on Non-Financial Matters and the 2024 Compensation Report were presented to shareholders, who accepted them in separate, non-binding consultative votes. Additionally, the operating and financial review of Alcon, alongside the annual financial statements and consolidated financial statements for 2024, received shareholder approval.
Dividend and Auditor Approvals
Alcon announced a gross dividend of CHF 0.28 per dividend-bearing share. After appropriating the dividend, any remaining available earnings will be carried forward. This decision reflects Alcon’s strong financial performance and commitment to returning value to its shareholders.
Shareholders also re-elected PricewaterhouseCoopers SA as the statutory auditors for the 2025 financial year. In addition, Hartmann Dreyer Attorneys-at-Law was re-elected as the independent representative, with their term extending until the 2026 AGM.
About Alcon
As the global leader in eye care, Alcon has been committed to helping people see brilliantly for over 75 years. With an extensive portfolio of products in Surgical and Vision Care, the company serves over 140 countries, improving lives through the treatment of conditions such as cataracts, glaucoma, retinal diseases, and refractive errors. Alcon’s products and services are backed by a team of more than 25,000 associates, working in partnership with Eye Care Professionals to enhance access to quality eye care worldwide. To learn more, visit www.alcon.com.